Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

The approval is based on Phase III FIBRONEER-IPF and FIBRONEER-ILD clinical trials conducted in parallel.

Nerandomilast met the primary endpoint in the FIBRONEER-IPF study. Credit: Tapati Rinchumrus / Shutterstock.com.

Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Japan is the fourth country to authorise nerandomilast. Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.